CommercialPrior AuthMedium impact
Intravitreal Angiogenesis Inhibitors
Blue Cross & Blue Shield of Mississippi·MS · Ophthalmology·Medical Policy
We identified it
Jun 20, 2026
Summary
This BCBSMS policy update establishes specific prior authorization requirements and coverage criteria for intravitreal angiogenesis inhibitors used to treat eye conditions. Four drugs (Byooviz, Eylea, Lucentis, and Pavblu) now require prior authorization with specific medical necessity criteria, while bevacizumab-based drugs are covered without prior auth for approved indications.
Action Required
Immediately: Billing team must update prior authorization processes for Byooviz (ranibizumab-nuna), Eylea (aflibercept), Lucentis (ranibizumab), and Pavblu (aflibercept-ayyh). Verify formulary coverage for each patient's specific benefit plan before prescribing. Providers must document age ≥18, specific diagnosis criteria, and specialist consultation requirements. Claims for services related to delivery/administration will be denied without approved prior authorization.